

# 1 Evaluation of silver 2 nanoparticles for the 3 prevention of SARS-CoV-2 4 infection in health workers: *in* 5 *vitro* and *in vivo*

6 Horacio Almanza-Reyes<sup>1\*</sup>, Sandra Moreno<sup>2</sup>, Ismael Plascencia-López<sup>3</sup>, Martha Alvarado-Vera<sup>1</sup>,  
7 Leslie Patrón-Romero<sup>4</sup>, Belén Borrego<sup>2</sup>, Alberto Reyes-Escamilla<sup>5</sup>, Daniel Valencia-Manzo<sup>5,6</sup>,  
8 Alejandro Brun<sup>2</sup>, Alexey Pestryakov<sup>7</sup>, Nina Bogdanchikova<sup>8</sup>

9  
10 <sup>1</sup>Cluster de Bioeconomía de Baja California, A.C.; [almanzareyes@hotmail.com](mailto:almanzareyes@hotmail.com)

11 <sup>2</sup>Centro de Investigación en Sanidad Animal. Instituto Nacional de Investigación y Tecnología  
12 Agraria y Alimentaria. Carretera de Valdeolmos-El Casar s/n Valdeolmos 28130. Madrid, Spain.  
13 [brun@inia.es](mailto:brun@inia.es)

14 <sup>3</sup>Faculty of Accounting and Administration, Autonomous University of Baja California; C.P.22390,  
15 Tijuana, Baja California, Mexico; [ismael@uabc.edu.mx](mailto:ismael@uabc.edu.mx)

16 <sup>4</sup>Faculty of Medicine and Psychology, Autonomous University of Baja California; C.P.22390,  
17 Tijuana, Baja California, Mexico; [leslie.patron@uabc.edu.mx](mailto:leslie.patron@uabc.edu.mx)

18 <sup>5</sup>Tijuana General Hospital; C.P. 22000, Tijuana, Baja California, Mexico;  
19 [direccion\\_sub\\_hgt@hotmail.com](mailto:direccion_sub_hgt@hotmail.com)

20 <sup>6</sup>Nursing Postgraduate, Iberoamericana University, Mexico City, C.P. 22500 Tijuana, Baja California,  
21 México; [daniel.valencia@tijuana.iberomx](mailto:daniel.valencia@tijuana.iberomx)

22 <sup>7</sup>Tomsk Polytechnic University; C.P. 634050, Tomsk, Russia; [pestryakov2005@yandex.ru](mailto:pestryakov2005@yandex.ru)

23 <sup>8</sup>Center of Nanoscience and Nanotechnology; UNAM (CNyN-UNAM), C.P.22860, Ensenada, Baja  
24 California, Mexico; [nina@cnyn.unam.mx](mailto:nina@cnyn.unam.mx)

25

26

27 \*Correspondence: [almanzareyes@hotmail.com](mailto:almanzareyes@hotmail.com); +52 (664) 830-3326.

28

## 29 Abstract

30 SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction  
31 between health care personnel and patients diagnosed with COVID-19, which allows virus to be  
32 easily spread between them and subsequently to their families and communities. Preventing

33 SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of  
34 infections and outbreaks during the pandemic considering that they work in high-risk areas. In this  
35 research, silver nanoparticles (AgNPs) were tested *in vitro* and shown to have an inhibitory effect  
36 on SARS-CoV-2 infection in cultured cells. Subsequently, we assess the effects of mouthwash and  
37 nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion  
38 in health workers consider as high-risk group of acquiring the infection in the General Tijuana  
39 Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19.  
40 We present a prospective randomized study of 231 participants that was carried out for 9 weeks  
41 (during the declaration of a pandemic). The "experimental" group was instructed to do  
42 mouthwash and nose rinse with the AgNPs solution; the "control" group was instructed to do  
43 mouthwashes and nose rinse in a conventional way. The incidence of SARS-CoV-2 infection was  
44 significantly lower in the "experimental" group (two participants of 114, 1.8%) compared to the  
45 "control" group (thirty-three participants of 117, 28.2%), with a 84.8% efficiency. We conclude  
46 that the mouth and nasal rinse with AgNPs helps in the prevention of SARS-CoV-2 infection in  
47 health personnel who are exposed to patients diagnosed with COVID-19.

## 48 **Introduction**

49 On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-  
50 19) a worldwide public health problem; the responsible agent was named the severe acute  
51 respiratory syndrome coronavirus-2 (SARS-CoV-2) [1]. An estimated of 132,730,691 infected cases  
52 and 2,880,726 deaths have being reported as of April 8<sup>th</sup>, 2021 worldwide [2]. The infection  
53 triggered by SARS-CoV-2 can cause symptoms that appear from 2 to 14 days after exposure to the  
54 virus [3]. Caring for SARS-CoV-2 patients is a high risk exposition and causes complications due to  
55 the high mortality and morbidity [4]. In turn, there is a risk of nosocomial infections among

56 patients with COVID-19 and patients without a diagnosis of atypical pneumonia [5]. To reduce the  
57 morbidity and morbidity rate of healthcare personal, a variety of public health interventions have  
58 been implemented, such as the adaptation of areas with negative air pressure, isolation areas for  
59 patients with COVID-19, and the mandatory use of personal protective equipment (gloves,  
60 goggles, overalls and N95/FFP2 respirators among others) to avoid contact with the respiratory  
61 and conjunctive tract [6]. International strategies focus on containment, diagnosis /monitoring,  
62 drug production and vaccines development against SARS-CoV-2 [7,8]. Different candidate drugs  
63 have been identified as antivirals against SARS-CoV-2 [9], but there are only very few drugs  
64 approved by the US Food and Drug Administration (FDA | |) [10]. Their efficacy and safety are still  
65 under evaluation. The main strategy to prevent SARS-CoV-2 infection would be vaccination. So far,  
66 a dozen vaccines have been approved by different international organizations [11–15], but global  
67 access to vaccines is one of the drawbacks, also vaccination strategies can take years to be an  
68 effective solution. On the other hand, no vaccine has been created so far against any coronavirus  
69 causing the last three pandemics such as SARS-CoV in 2002 [16], MERS-CoV in 2012[17] and SARS-  
70 CoV-2 in 2019 [18]. Classic or traditional (attenuated or inactivated) vaccines have not worked  
71 because an Antibody-dependent enhancement (ADE) occurs [19]. Antibodies produced with one  
72 specific coronavirus subtype work, but they are not necessarily neutralizing, but rather opsonizing,  
73 leading to increased viral infectivity [20]. This leads to the fact that ADE-mediated secondary  
74 heterotypic infections caused by different coronavirus subtypes is the greatest risk factor [21,22].  
75 SARS-CoV-2 infection in hospital areas is especially problematic, since the close interaction  
76 between health care personnel and patients diagnosed with COVID-19 which allows virus to be  
77 easily spread between them and subsequently to their families and communities. On the other  
78 hand, in previous research, the *in vitro* antiviral effect of AgNPs has been demonstrated [23,24].  
79 Here, we confirmed the inhibitory effect of AgNPs in SARS-CoV-2 replication in cultured cells. For

80 these reasons, a non-pharmaceutical public health intervention consisting of mouthwash and nose  
81 rinse with an AgNPs solution is proposed in order to reduce morbidity among healthcare  
82 personnel exposed to SARS-CoV-2 virus. We designed a prospective randomized controlled study  
83 of two-group (experimental vs. control) to evaluate the efficacy of mouthwash and nasal rinse  
84 with AgNPs solution for preventing SARS-CoV-2 infection in the health personnel at the General  
85 Tijuana Hospital in Mexico who works in high-risk areas with direct contact with patients infected  
86 and diagnosed with COVID-19.

## 87 **Materials and Methods**

### 88 **Virus and cells**

89 All *in vitro* studies were performed using the SARS-CoV-2 NL/2020 strain  
90 (BetaCoV/Netherlands/01) provided by the European Virus Archive global (EVAg). VeroE6 cells  
91 (ATCC Cat.No. CRL-1586), obtained from the cell repository at Centro de Investigación en Sanidad  
92 Animal, (CISA-INIA, Valdeolmos, Spain) were grown in Dulbecco's modified Eagle's medium  
93 (DMEM) supplemented with 10% fetal bovine serum (FBS), and L-glutamine (2 mM), penicillin (100  
94 U/ml) and streptomycin (100 µg/ml), in a humid atmosphere of 5% CO<sub>2</sub> at 37°C.

### 95 **Cell viability assays**

96 Vero E6 cells were seeded in 96-well plates, and 24 hours later, when 80% confluence was  
97 reached, Argovit was added to the medium at serial two-fold dilutions, in triplicates. Vero E6 cells  
98 viability was tested in a long exposure experiment: Argovit (starting from a 1/2 dilution) was kept  
99 in the culture medium for 24, 48 and 72 hours. The treated cells were maintained at 37°C in a 5%  
100 CO<sub>2</sub> incubator and daily checked at the microscope. Viability of Vero E6 cells after treatment at the  
101 indicated times was checked using the MTS Cell Proliferation Assay (Promega) following

102 manufacturer's instructions. Viability percentages were calculated as the ratio  $OD_{450}$  nm treated  
103 wells/  $OD_{450}$  nm Argovit-free wells x 100. The ODs corresponded to the mean of three replicas and  
104 were corrected by the corresponding blank wells without cells.

## 105 ***In vitro* infection experiments**

106 Confluent monolayers of Vero E6 cells seeded on 12-well plates were infected with SARS-Cov2  
107 at a multiplicity of infection (moi) of 0.001 plaque-forming units (pfu) per well in presence of  
108 metallic silver at serial two-fold dilutions from  $\frac{1}{2}$  to 1/2048 (concentrations of 0.5% to 0.0004%).  
109 Plates were maintained at 37°C for three days. At 72 hpi supernatants were collected and titrated  
110 in Vero E6 cells grown in 12-well plates. After 45 minutes of adsorption, the inoculum was  
111 removed and semi-solid medium with 1% carboxymethyl-cellulose in 1X DMEM 5% FBS was  
112 added. Plates were incubated for 72 hours, then fixed and crystal violet stained. Plaques were  
113 counted and the percentage of infectivity for each Argovit dilution was calculated as follows:  $[1 -$   
114  $(\text{number of plaques at the corresponding Argovit dilution}) / \text{number of plaques with medium}$   
115  $\text{alone}] \times 100$ . Controls corresponding to 100% infectivity (infection in the absence of Argovit) as  
116 well as 100% viability (non-infected cells in medium containing Argovit) were also included.  $IC_{50}$   
117 values were calculated using GraphPad software (Prism).

## 118 **Ethical considerations**

119 The *in vivo* study was approved by the Research Ethics Committee of General Tijuana Hospital  
120 of the Institute of Public Health Services of the State of Baja California with favorable opinion  
121 number CONBIOETICA-02-CEI-001-20170 and was conducted in accordance with the Declaration  
122 of Helsinki. Signed consent was obtained from all participants. The objective of the study, the  
123 methodology and details of the experimental procedures and voluntary character of participation  
124 (including the right to withdraw from the study at any moment) were explained to all the

125 participants. Participants were also informed on the anonymity and confidentiality of the data  
126 they reported during the study.

## 127 **Materials**

128 The hygiene product for mouthwash and nasal rinse ARGOVIT® AgNPs from the Investigation  
129 and Production Center Vector-Vita Ltd., made in Novosibirsk, Russia was applied. Metallic silver,  
130 polyvinylpyrrolidone, hydrolyzed collagen and distilled water concentrations in this solution are  
131 0.06, 0.63, 0.31, and 99 wt.%, respectively. ARGOVIT® is registered in Russia as an oral and nasal  
132 hygiene product since 2015.

## 133 **Study design**

134 The *in vivo* study was carried out in the areas converted to care for patients diagnosed with  
135 atypical pneumonia and/or COVID-19 at General Tijuana Hospital belonging to the Mexican  
136 Ministry of Health. A 2-group randomized parallel study was conducted to compare the efficacy of  
137 mouthwash and nose rinse with the AgNPs 1 wt. % (0.6 mg of metallic Ag per mL) or direct spray  
138 to the oral cavity (experimental group); the second group was instructed to do mouthwash and  
139 nose rinse in a conventional way (control group). The investigation lasted 63 days (9 weeks) in the  
140 COVID-19 pandemic period, beginning in April 7 through June 9, 2020.

## 141 **Participants and environment**

142 For the *in vivo* study, 231 volunteers were selected from General Hospital Tijuana. Men and  
143 women were included among the participants, ranging from 18 to 65 years of age, and various  
144 occupations. Personnel excluded from the study included persons with history of hypersensitivity  
145 to silver (rashes and other contraindications), a history of SARS-CoV-2 infection in the three  
146 months prior to the start of the study, any respiratory distress, and refusal to sign the informed  
147 consent.

## 148 **Instruments**

149 The participants in the *in vivo* study were briefed on the objective of the study and were  
150 instructed on how to carry out the mouthwash and nose rinse. Subsequently, they were asked to  
151 complete a questionnaire where first identified the general data on the participants (Table 1.) and  
152 the second part, the participants reported weekly data related to their activities pertaining the  
153 study and their state of health (Table 2.). Experimental group were questioned about the presence  
154 of adverse effects by mouthwash and nose rinse. The diagnosis of COVID-19 was made by  
155 monitoring the signs and symptoms of the participants to finally confirm the infection status by  
156 RT-PCR (SuperScript III Platinum, Invitrogen, EEUU; Integrated DNA Technologies, Coralville,  
157 EEUU). Additionally, the two study groups were randomly selected for CT (Toshiba Aquilion 16,  
158 Japan) chest scan, RT-PCR analysis and clinical evaluation, to confirm the diagnosis of COVID-19.  
159 Participants with confirmed COVID-19 diagnosis were granted sick leave or were hospitalized.

## 160 **Randomization and experimental intervention**

161 Eligible participants for the *in vivo* study were randomized using a computer generated block  
162 scheme and stratified according to duty position, work shifts and the area/department of the  
163 service at General Tijuana Hospital. Individuals from experimental group were provided with a 50  
164 mL spray bottle containing AgNPs solution with 1 wt% concentration (0.6 mg/mL metallic silver).  
165 They were instructed to mix 4 to 6 spray shots (corresponding to volume ~ 0.5 mL) of this solution  
166 with 20 mL of water and to gargle with obtained solution for 15 to 30 seconds at least 3 times a  
167 day, also nasal lavages on the inner part of the nasal alae and nasal passage with the same  
168 solution using a cotton swap twice a day. As a second option, they were instructed to cover evenly  
169 the oral cavity with the direct 1 to 2 spray shots of solution without its previous dilution in water.  
170 Participants of the control group were instructed to do mouthwash and nose rinse with a  
171 conventional mouthwash the way they normally did before the study.

## 172 **Data analysis**

173 Data analysis was performed through the SPSS statistical program (version 26). Descriptive  
174 analysis was done with frequencies, percentages, means and ranges. To check the statistical  
175 difference between the results of the experimental and control groups, the Pearson's "Chi-Square"  
176 tests, the "Fisher's exact test" and the "likelihood ratio" were used. The symmetry measures for 2  
177 x 2 contingency tables were determined by the Statistics of "Phi", "Contingency Coefficient" and  
178 "Cramer's V". A logistic regression was performed to corroborate the efficacy of performing  
179 mouthwash and nose rinse with AgNPs and its impact on the incidence of SARS-CoV-2 infections  
180 among the participants under similar conditions. Likewise, the Chi-Square statistic was applied to  
181 determine the p-value in order to determine the homogeneity or heterogeneity between the  
182 experimental group and the control group.

## 183 **Results**


### 184 **Antiviral activity of AgNPs in Vero E6 cell cultures**

185 To determine the efficacy of AgNPs against SARS-CoV-2 *in vitro*, we first analyzed its  
186 cytotoxicity on cultured Vero E6 cells. Cells were seeded in 96-iwell plates and two-fold serial  
187 dilutions of AgNPs added to the medium, in triplicates. The cells were then incubated for 24, 48 or  
188 72 hours. Cells grown in the presence of AgNPs over 24 hours showed the highest viability values  
189 over 1/32 dilution (or 0.03% of AgNPs) (Figure 1A). In order to ensure viral infection, further  
190 experiments were performed with [AgNPs]  $\leq$  0.03%. To analyze the effect of AgNPs on virus  
191 infectivity Vero E6 cells were infected with a fixed amount of virus and different concentrations of  
192 AgNPs, starting at 0.03%, were added to cells. At 72 hours post-infection (pi) supernatants were  
193 collected and titrated in order to determine virus yields normalized to those reached in medium

194 alone (Figure 1B). Although AgNPs did not totally abolish viral production, infection was clearly  
 195 controlled to some extent with a reduction of about 80% at a concentration of 0.03%. A 50%  
 196 inhibitory concentration was determined by curve fitting (non-linear regression) (Fig. 1BC).

197

**Fig. 1. Antiviral activity of AgNPs in Vero E6 cell cultures.**



198

199 **A.** Effect of AgNPs on viability of cultured Vero cells. Serial two-fold dilutions of AgNPs were added in triplicate to  
 200 the medium of Vero cells seeded in 96-well plates. Viability at 24 (white bars), 48 (grey bars) and 72 h (black bars) was  
 201 checked by the MTS Cell Proliferation Assay (Promega) and calculated as described in Methods. Statistically significant  
 202 differences when compared to the corresponding 100% of cell viability (by 2 way ANOVA) are indicated. \*,  $p < 0.05$ ; \*\*\*,  
 203  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ . **B.** Percentages of infectivity values for each AgNPs concentration. The values were  
 204 normalized to those in the absence of Argovit (medium, 100%) and fitted using a non-linear regression algorithm.  $IC_{50}$ :  
 205 50% inhibitory concentration. **C.** Representative SARS-CoV-2 plaque formation in presence of different dilutions of  
 206 AgNPs.

## 207 Description of the groups

208 From the total of 231 participants, 114 were assigned to the experimental group, including 41  
 209 men (36%) and 73 women (64%), with an average age of 35 years. The control group included 117

210 participants, 40 men (34%) and 77 (66%) women with an average age of 33 years. 66% of the  
 211 participants in the experimental group were vaccinated against influenza virus during the last year,  
 212 while in the control group the vaccinated participants accounted for 86%. Regarding the  
 213 profession of health personnel, there were 8% doctors, 80% nurses and 12% administrative in the  
 214 experimental group and 3% doctors, 88% nurses and 9% administrative in the control group. A  
 215 reduced number of participants reported being smokers (9% in the experimental group vs. 19% in  
 216 the control group); as well as not having chronic diseases such as: diabetes (3% in the  
 217 experimental group vs. 5% in the control group); hypertension (6% in the experimental group vs.  
 218 4% in the control group); and asthma (4% in the experimental group vs 3% in the control group).  
 219 Most participants reported becoming ill with respiratory tract infections  $\leq 2$  times in the past year  
 220 (89% in the experimental group and 91% in the control group). The frequency of daily  
 221 handwashing and mouthwash prior to the study, in the experimental group were: 6.3  
 222 handwashing and 0.95 average daily mouthwash, and in the control group 8.9 handwashing and  
 223 0.52 average daily mouthwash. Studied groups characteristics and Chi Square tests results which  
 224 determine the significance of differences between groups are presented in Table 1.

225 **Table 1. Characteristics of the experimental and control group.**

Basic characteristics	Experimental group (n=114)	Control group (n=117)	$\chi^2$	P value
<b>Gender (Male/Female) (%)</b>	41 / 73 36% / 64%	40 / 77 34% / 66%	0.80	.785
<b>Age (average/range)</b>	(35) (range 20-73)	(33) (range 21-56)	14.749	.004
<b>Anti-influenza vaccination (number of individuals) (%)</b>	(75) 66%	(101) 86%	13.422	.000
<b>Occupation (Doctor/nurse/administrative) (%)</b>	9 / 91 / 14 8% / 80% / 12%	4 / 103 / 10 3% / 88% / 9%	3.294	.210
<b>Smoking (never/previous/current) (%)</b>	104 / 8 / 2 91% / 7% / 2%	95 / 10 / 12 81% / 9% / 10%	7.734	.021
<b>Body Mass Index (mean)</b>	25.95	28.93	24.554	.000
<b>Diseases</b>			5.187	.273

<b>(number of individuals) (%)</b>				
<b>Nothing</b>	93(82.5%)	91 (77.77%)		
<b>Diabetes</b>	4 (3.5%)	6 (5.1%)		
<b>Hypertension</b>	7 (6.1%)	5 (4.4%)		
<b>Asthma</b>	5 (4.4%)	3 (3%)		
<b>Other</b>	4 (3.5%)	12 (10.3%)		
<b>Annual frequency of RTIs in preceding year (mean) (0/1-2/≥3)</b>	(0.88) (61 / 40 / 13)	(0.94) (51 / 56 / 10)	3.913	.150
<b>Frequency of daily gargles before the study (mean) (0/1-2/≥3)</b>	(0.95) (60 / 45 / 9)	(0.52) (87 / 20 / 10)	14.591	.000
<b>Daily handwashing before the study (mean)</b>	6.3	8.9	20.818	.000
<b>Daily handwashing in present study (mean)</b>	11.6	13.5	1.239	.271

226 RTIs: Respiratory tract infections.

227  $\chi^2$ : Chi-square test to determine the p-value of homogeneity or difference between groups.

## 228 **Results analysis**

229 The incidence of SARS-CoV-2 infection ( $p = 0.000$ ), was significantly lower in the experimental  
 230 group vs the control group, where 1.8% (2 participants out of 114) and 28.2% (33 participants out  
 231 of 117) were infected respectively (Table 2); frequency of mouthwashes (gargles and/or spray  
 232 application) and nasal application daily with AgNPs, performed only by the experimental group, on  
 233 average 2 mouthwashes made by 28 participants who only did it in the form of gargles, 2 daily  
 234 applications by 34 participants who only used it in spray; while the 52 participants who chose to  
 235 do both types of rinses, performed them on average 2 times as a gargle and 4 times as a spray  
 236 application; on average 0.70 nasal rinse made by 64 participants; weekly number of contacts with  
 237 patients diagnosed with COVID-19 or atypical pneumonia during the study period: (0 - 860, 169 on  
 238 average) in the experimental group and (0 to 729, 146 on average) in the control group;  
 239 percentage of individuals who presented symptoms of respiratory tract infection (RTI's) at some  
 240 point during the study; 18.4% in the experimental group and 35.8% in the control group; no  
 241 adverse reactions were reported by performing mouthwash and nose rinse with AgNPs.

242

Table 2. Prevention of SARS-CoV-2 infection in health workers.

Variables	Experimental group (n=114)	Control group (n=117)	$\chi^2$	P value
Infected cases SARS-CoV-2 (number of individuals) (%)	2 (1.8%)	33 (28.2%)	31.423	0.000
Participants that did mouthwashes by gargle (number of individuals) (%)	28 (24.56%)	28 (23.93%)	0.013	0.838
Participants that did mouthwashes by spray (number of individuals) (%)	34 (29.82%)	-	-	-
Participants that did mouthwashes by gargle and spray (number of individuals) (%)	52 (45.61%)	-	-	-
Participants that did nasal rinses (number of individuals) (%)	64 (54.70%)	21(17.95%)	36.18	0.00
Number of daily gargles with AgNPs (mean)	2	2.14	0.1667	0.563
Number of mouthwashes with AgNPs spray (mean)	2	-	-	-
Number of mouthwashes by gargles and spray (mean)	2 and 4	-	-	-
Number of nasal rinses (mean)	0.70	0.25	5.031	0.00
Adverse reactions reported from using mouthwash with silver nanoparticles	0	-	-	-
Number of weekly contacts with patients COVID-19 (range) (mean)	(0-860) (169)	(0-729) (146)	-	-
Symptoms of RTIs (number of individuals) (%)	21 (18.4%)	42 (35.8%)	8.891	.003
Occupation of infected individuals (doctor/nurse/administrative)	0/2/0	2/29/2	.515	.773

243 AgNPs: silver nanoparticles.

244 RTIs: Respiratory tract infections.

245  $\chi^2$ : Chi-square test to determine the p-value.

246

247 Pearson's Chi-Square tests, the "Fisher's exact test" and the "likelihood ratio" were run to

248 check the statistical difference between the experimental and control groups. If the use of AgNPs

249 had not been effective and 1) the protection measures used in the General Tijuana Hospital were

250 very effective, the same low contagion level (1.8%) would have been presented in both groups; 2)  
 251 if the protection measures were not effective, the same high contagion level (28.2%) would have  
 252 been presented in both groups. Results were significant at 99% reliability for both one-tailed and  
 253 two-tailed tests verified the difference in group results. The predictive model based on the  
 254 experimental data reports that the odds of a participant who is treated with the AgNPs are 22  
 255 times higher than those of a participant who is not treated. The logistic model predicts that if all  
 256 participants had mouthwashes and nasal rinses, the probability of success (they did not become  
 257 infected with SARS-CoV-2) would be 84.8%. Table 3 shows the good fit of the data to the model  
 258 taking into account that the probability of non-contagion depends on whether or not performed  
 259 AgNPs solution, but the number of mouthwashes and nasal rinse on average per day (gargling and  
 260 nasal rinse, spray application or combined) was also taken into account.

261 **Table 3. Results of the logistic regression of SARS-CoV-2 infection between control and experimental groups.**

Variables	B (SE)	Exp (B)	Wald	Sig.	R2 Cox & Snell/Nagelkerke
<b>a) SARS-CoV-2 infection between control group and experimental group with AgNPs mouthwash</b>					
Constant	.934 (.205)	2.545	20.682	.000	
Mouthwash and nose rinse with AgNPs (Gargles)	3.091 (.742)	22.000	17.33	.000	
					.149 / .259
<b>b) SARS-CoV-2 infection between control group and experimental group with combined mouthwash with AgNPs (gargle and spray)</b>					
Constant	3.280 (.732)	26.58	20.058	.000	
Mouthwash and nose rinse with AgNPs (Gargles)	4.692 (1.465)	109.065	10.259	.001	
Mouthwash with AgNPs (Gargles and spray)	-.190 (.109)	.827	3.032	.082	
					.158 / .276

262 B (SE): B is the same linear regression value b that we need to substitute to obtain the ordinate at the  
 263 origin (Constant) and the slope of the line of the variable, in parentheses is the Standard Error (SE).

264 Exp (B): Odds Ratio, is an indicator of the change in the ratios, as a result of a change in the predictor.

265 Wald: Statistical test analogous to the t-statistics test in linear regression to see the contribution of the  
266 predictive variables. Wald =  $b / SE_b$ .

267 Sig: Level of significance.

268 R2: Goodness of fit of the model to the logistic curve with the Cox & Snell / Nagelkerke methods.

269

270 The dichotomous independent variable (participated in the experiment or not) is highly  
271 significant according to the value of the Wald statistic. The interesting thing about the logistic  
272 regression is the statistic Exp (B), which in this case tells us that for each person who “DOESN'T  
273 become infected” with SARS-CoV-2 in the control group, there are 22 people “NOT INFECTED”  
274 when they perform mouthwash and nose rinses with AgNPs in the experimental group in similar  
275 environments or under similar conditions. To find out whether the number of times mouthwashes  
276 and nasal rinse is performed with AgNPs per day has an effect, the quantitative variable was added  
277 to the dichotomous variables of the previous model where the average number of mouthwashes  
278 and nasal rinse was combined as in our sample. It was 2 gargle mouthwashes, 1 nasal rinse, and 2  
279 spray mouthwashes. When we assume that 4 mouthwashes were performed daily (2 gargle and 2  
280 spray) and 1 nasal rinse, the model improves with respect to only saying that the person  
281 participated in the experiment without considering the number of applications. The EXP (B)  
282 Statistic rises from 22 to 109 when considering mouthwash in both gargles and spray. That is, for  
283 each person who becomes infected with SARS-CoV-2 by performing 4 mouthwashes (2 gargles and  
284 2 spray) and 1 nasal rinse, per day 109 people will not be infected.

## 285 Discussion

286 Silver nanoparticles are known to have a powerful antimicrobial effect and there have been  
287 several studies that also demonstrated their antiviral effect [25]. The mechanism by which AgNPs  
288 interact with viruses is not yet clear, but it has been proposed that AgNPs, as well as other metallic

289 nanoparticles, interfere with the structural proteins of the virus by inhibiting their ability to bind  
290 with cell receptors or bind to genetic material of viruses by inhibiting their replication[26]. Since  
291 the nanoparticles used in these experiments are mixed with hydrolyzed collagen, a compound that  
292 stabilizes nanoparticles and reduces its toxicity in cell culture [28], we were able to assess higher  
293 concentrations than those used in other articles. Jeremiah et al. showed that in Vero E6 cells  
294 AgNPs alone are toxic at concentrations of 100 ppm. In contrast, we observed that collagen AgNPs  
295 are not toxic up to concentrations of 0.03% (312 ppm). Despite this fact, the toxicity of silver  
296 nanoparticles in cell culture narrows the range of concentrations at which we can study  
297 therapeutic effects against viral infections *in vitro*. Taking this limitation into account we could  
298 observe a clear dose-dependent inhibitory effect over SARS-CoV-2 infectivity.

299 To our knowledge, this study is the first experimental trial where AgNPs are applied as a  
300 mouthwash and nose rinse solution for the prevention of SARS-CoV-2 infection in health care  
301 personnel working with COVID-19 diagnosed patients. The study was carried out in a prospective,  
302 controlled and randomized way for 9 weeks in the period of pandemic by COVID-19 from April to  
303 June 2020 in Tijuana Baja California, Mexico. The characterization of the two groups showed no  
304 significant statistical differences in gender, occupation and comorbidities related to the  
305 complication of SARS-CoV-2 infection. However, a statistically significant difference was identified  
306 in variables such as: age ( $p = 0.004$ ), average age 35 in the experimental group and average age 33  
307 in the control group; anti-influenza vaccination ( $p = 0.000$ ), (66%) in the experimental group and  
308 (86%) in the control group, even though, vaccination against influenza virus reduces  
309 morbidity/mortality among medical personnel exclusively against influenza virus, but does not  
310 have any antigenic similarity with SARS-CoV-2 virus, as an example in this study, the control group  
311 reported a higher percentage of participants vaccinated against influenza and a higher percentage  
312 of infection by SARS-Cov2; Body Mass Index ( $p = 0.000$ ), (25.95) in the experimental group and

313 (28.93) in the control group, both groups classifying within the 25-29 Overweight level; frequency  
314 of daily gargles before the study ( $p = 0.000$ ), (0.95); frequency of daily handwashing before the  
315 study ( $p = 0.000$ ), (6.3) in the experimental group and (8.9) in the control group, the experimental  
316 group had the lowest number of COVID-19 infections, being the group that washed their hands  
317 less frequently, this indicates that AgNPs contributed to mitigating the SARS-CoV-2 infection in the  
318 experimental group, consistent handwashing has previously been recognized as a protective factor  
319 against SARS and influenza [29], in addition, most respiratory pathogens are spread by direct  
320 contact, droplets, and fomites [30]; the most important statistically significant difference, the  
321 incidence of SARS-CoV-2 infection was significantly lower in the experimental group (1.8%) than  
322 the control group (28.2%) ( $p=0.000$ ); and finally, the report of symptoms related to the SARS-CoV-  
323 2 infection, there was a statistically significant difference ( $p = 0.003$ ) reported by the experimental  
324 group (18.4%), while in the control group (35.8%).

325 These results corroborate the relevance of oral and nasal hygiene with AgNPs in the  
326 prevention of respiratory tract infection to minimize the risk of contagion by COVID-19 in health  
327 personnel. Scientific evidence supports preventive oral and nasal health regimens, including the  
328 use of mouthwashes, gargles, and nasal washes, as important components of SARS-CoV-2  
329 infection control practices [31–33]. Using a logistic regression, the strong relationship between the  
330 fact of mouthwashes and nose rinse in the health personnel and the mitigation of the SARS-CoV-2  
331 contagion with an efficiency of 84.8% is proved. The results provide clinical evidence to confirm  
332 the prevention of SARS-CoV-2 infection in health personnel who performed mouthwash and nose  
333 rinse solution with AgNPs. In the midst of the global pandemic, the results of *in vitro* infection  
334 experiments (effect of AgNPs on virus infectivity and determination of the 50% inhibitory  
335 concentration) and Argovit registration as an oral and nasal hygiene product in Russia since 2015,  
336 and with antimicrobial action for oral and nasal hygiene since 2019, were decisive to apply the

337 AgNPs *in vivo* in the oral and nasal cavity to confirm its effects against SARS-CoV-2. The present  
338 study also showed that no harmful side effects were observed in the 114 participants who used  
339 AgNPs as a mouthwash and nose rinse solution for 9 weeks.

340 The relevance of mouthwash and nasal rinses as a prevention strategy for mitigating SARS-  
341 CoV-2 infections among health personnel also extends to other high-risk areas such as dental  
342 procedures, in these cases, specific protocols are suggested to avoid COVID-19 contamination. The  
343 oropharynx and nasopharynx are the initial entry sites where SARS-CoV-2 replicates and can  
344 produce a viral load of  $1.2 \times 10^8$  infectious copies / per mL [34]. The odontologist works with a high  
345 risk of exposure during routine dental procedures. In addition, the use of different devices that  
346 generate a high amount of aerosols (rotary instruments and ultrasounds), which can be inhaled  
347 through the respiratory route, these aerosols can also carry viral particles that come into contact  
348 with the conjunctiva and also cause infection, on the other hand these residues can be deposited  
349 on different surfaces, on the work clothes, masks, hands and clothes of the patient. Dental  
350 cabinets are considered a possible source of contamination and nosocomial infection [35].  
351 Contamination by nasal excretions can carry thousands of infectious particles, since a higher viral  
352 load has been demonstrated in the nasal cavity compared to the oral cavity [36]. Recent reports  
353 indicate that total anosmia or partial loss of the sense of smell are early markers of SARS-CoV-2  
354 infection. This phenomenon can be caused by the expression of the receptors of the  
355 transmembrane protein of the angiotensin converting enzyme II (ACE2) and by a type II  
356 transmembrane serine protease (TMPRSS2), responsible for the entry of the virus into  
357 nasopharyngeal cells and present direct damage secondary to SARS-CoV-2 viral replication in  
358 olfactory receptor neurons (ORNs) located in the olfactory epithelium [37]. These results justify  
359 making changes to the international recommendations [35] on new dental clinical practices and  
360 the prevention of SARS-CoV-2. Since the dental clinic procedure requires that the patient, after

361 passing the sanitary filter, has to perform a mouth rinse (on average 30 minutes before the  
362 consultation), followed by a second mouth rinse when seated in the dental chair. At no time do  
363 international recommendations[35] speak of nasal washes, when it has been demonstrated that  
364 by nasal exhalation the spread of SARS-CoV-2 to health personnel can occur. The evidence  
365 presented in this study suggests that the application of mouthwashes and nose rinse can  
366 significantly reduce the viral load in these areas, to reduce transmission, in addition to the use of  
367 personal protective equipment by healthcare personnel.

368 The lack of efficient and specific SARS-CoV-2 antiviral therapies could be due in large part to  
369 the underuse of nanotechnologies [38], non-pharmaceutical therapies based on nanotechnology  
370 applications are needed as preventive measures, to mitigate the nosocomial transmission of SARS-  
371 CoV-2 among health personnel. We present a new intervention strategy that uses AgNPs as a  
372 mouthwash and nasal rinse solution that can reduce the spread, transmission and/or  
373 pathogenicity of SARS-CoV-2 associated with COVID-19. Due to the frequent generation of  
374 aerosols by direct treatment with patients with COVID-19, the associated risk of virus transmission  
375 was very low among health personnel who performed mouthwashes and nasal washes with  
376 AgNPs. The antiviral effect of mouthwashes and nose rinse with AgNPs can decrease the viral load  
377 in the oral and nasal cavity, as well as inhibit the proliferation of the virus and temporarily reduce  
378 the risk of transmission. These results were demonstrated in the clinical field of the health  
379 personnel of the Tijuana General Hospital.

## 380 **Conclusions**

381 This prospective randomized study demonstrates that mouthwash and nose rinse with AgNPs  
382 is effective in decreasing SARS-CoV-2 infection rate. To our knowledge, this study is the first

383 experimental *in vitro* e *in vivo* trial where AgNPs as mouthwash and nasal rinse solution are  
384 applied for SARS-CoV-2 contagion prevention. The results of this investigation are revealing and  
385 encouraging, due to the fact that the health personnel exposed to an excessive viral load due to  
386 the number of COVID-19 patients attended (169 patients attended on average per week per  
387 person) were not infected, which is attributed to rinsing with AgNPs. Proved its inhibitory effect on  
388 SARS-CoV-2 infectivity *in vitro* it is inferred that the use of AgNPs as a mouthwash and nose rinse  
389 will be very useful as a prophylactic for the prevention of SARS-CoV-2, not only for health care  
390 personnel, but also as additional protection for the general population.

## 391 **Acknowledgments**

392 The authors of this study would like to thank the staff of General Tijuana Hospital for their  
393 invaluable participation in this research during the extremely difficult period of the COVID-19  
394 pandemic. The health care personnel are under intense workout during this pandemic. The  
395 authors would also like to thank CONACyT “International Network of Bionanotechnology with an  
396 Impact on Biomedicine, Food and Biosafety” and Tomsk Polytechnic University Competitiveness  
397 Enhancement Program, project VIU-RSCBMT-197/2020 for their important collaboration in the  
398 field of fundamental and applied research on nanomaterials in nanomedicine.

## 399 **References**

- 400 1. World Health Organization. Archived: WHO Timeline - COVID-19. In: Archived: WHO  
401 Timeline - COVID-19 [Internet]. [cited 30 Jul 2020]. Available: [https://www.who.int/news-](https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19?gclid=CjwKCAjw34n5BRA9EiwA2u9k385WKHmODGM3irOwTWLJfwg96XUtxDPUzIIPZW)  
402 [room/detail/27-04-2020-who-timeline---covid-](https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19?gclid=CjwKCAjw34n5BRA9EiwA2u9k385WKHmODGM3irOwTWLJfwg96XUtxDPUzIIPZW)  
403 [19?gclid=CjwKCAjw34n5BRA9EiwA2u9k385WKHmODGM3irOwTWLJfwg96XUtxDPUzIIPZW](https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19?gclid=CjwKCAjw34n5BRA9EiwA2u9k385WKHmODGM3irOwTWLJfwg96XUtxDPUzIIPZW)  
404 [hrRxp5qAOCYmJMchoCEmwQAvD\\_BwE](https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19?gclid=CjwKCAjw34n5BRA9EiwA2u9k385WKHmODGM3irOwTWLJfwg96XUtxDPUzIIPZW)

- 405 2. World Health Organization. Coronavirus disease (COVID-19) pandemic. In: Coronavirus  
406 disease (COVID-19) pandemic. [Internet]. 2020. Available:  
407 <http://www.who.int/emergencies/diseases/novel-coronavirus-2019>
- 408 3. Centers for Disease Control and Prevention. Symptoms of Coronavirus. 2020. Available:  
409 <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>
- 410 4. Lan FY, Wei CF, Hsu YT, Christiani DC, Kales SN. Work-related COVID-19 transmission in six  
411 Asian countries/areas: A follow-up study. PLoS One. 2020;15: 1–11.  
412 doi:10.1371/journal.pone.0233588
- 413 5. Wong SCY, Kwong RTS, Wu TC, Chan JWM, Chu MY, Lee SY, et al. Risk of nosocomial  
414 transmission of coronavirus disease 2019: an experience in a general ward setting in Hong  
415 Kong. J Hosp Infect. 2020;105: 119–127. doi:10.1016/j.jhin.2020.03.036
- 416 6. Making MOF, Zhu N, Zhang D, Wang W, Li XW, Yang B, et al. Personal protective equipment  
417 for COVID-19. N Engl J Med. 2020;13: 19–21. doi:10.23937/2378-3664.1410019
- 418 7. Wee LE, Hsieh JYC, Phua GC, Tan Y, Conceicao EP, Wijaya L, et al. Respiratory surveillance  
419 wards as a strategy to reduce nosocomial transmission of COVID-19 through early  
420 detection: The experience of a tertiary-care hospital in Singapore. Infect Control Hosp  
421 Epidemiol. 2020;41: 820–825. doi:10.1017/ice.2020.207
- 422 8. Ho HJ, Zhang ZX, Huang Z, Aung AH, Lim WY, Chow A. Use of a real-time locating system for  
423 contact tracing of health care workers during the COVID-19 pandemic at an infectious  
424 disease center in singapore: Validation study. J Med Internet Res. 2020;22.  
425 doi:10.2196/19437

- 426 9. Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates  
427 against SARS-CoV-2 from FDA-approved drugs. *Antimicrob Agents Chemother*. 2020;64.  
428 doi:10.1128/AAC.00819-20
- 429 10. Park SJ, Yu KM, Kim Y II, Kim SM, Kim EH, Kim SG, et al. Antiviral efficacies of FDA-approved  
430 drugs against SARS-COV-2 infection in ferrets. *MBio*. 2020;11: 1–10.  
431 doi:10.1128/mBio.01114-20
- 432 11. Logunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatulin AI, Zubkova O V, Dzharullaeva  
433 AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost  
434 COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.  
435 *Lancet* (London, England). 2021;397: 671–681. doi:10.1016/S0140-6736(21)00234-8
- 436 12. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a  
437 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years  
438 or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;396:  
439 479–488. doi:10.1016/S0140-6736(20)31605-6
- 440 13. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and  
441 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report  
442 of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396: 467–478.  
443 doi:10.1016/S0140-6736(20)31604-4
- 444 14. Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA  
445 Vaccine against SARS-CoV-2 — Preliminary Report. *N Engl J Med*. 2020;383: 1920–1931.  
446 doi:10.1056/nejmoa2022483

- 447 15. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 Trial of a SARS-CoV-2  
448 Recombinant Spike Protein Nanoparticle Vaccine. *N Engl J Med*. 2020;383: 2320–2332.  
449 doi:10.1056/nejmoa2026920
- 450 16. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization  
451 of viruses related to the SARS coronavirus from animals in Southern China. *Science* (80- ).  
452 2003;302: 276–278. doi:10.1126/science.1087139
- 453 17. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a  
454 novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*. 2012;367:  
455 1814–1820. doi:10.1056/NEJMoa1211721
- 456 18. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus  
457 causing severe pneumonia in human: a descriptive study. *Chin Med J (Engl)*. 2020;133:  
458 1015–1024. doi:10.1097/CM9.0000000000000722
- 459 19. Yip MS, Cheung CY, Li PH, Bruzzone R, Peiris JSM, Jaume M. Investigation of Antibody-  
460 Dependent Enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis  
461 of SARS. *BMC Proc*. 2011;5: P80. doi:10.1186/1753-6561-5-S1-P80
- 462 20. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, et al. Anti-Severe Acute Respiratory  
463 Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH-  
464 and Cysteine Protease-Independent Fc R Pathway. *J Virol*. 2011;85: 10582–10597.  
465 doi:10.1128/jvi.00671-11
- 466 21. Li L, Wo J, Shao J, Zhu H, Wu N, Li M, et al. SARS-coronavirus replicates in mononuclear cells  
467 of peripheral blood (PBMCs) from SARS patients. *J Clin Virol*. 2003;28: 239–244.

468 doi:10.1016/S1386-6532(03)00195-1

469 22. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the  
470 pathogenesis of SARS. *J Exp Med*. 2005;202: 415–424. doi:10.1084/jem.20050828

471 23. Ochoa-meza AR, Álvarez-sánchez AR, Romo-quiñonez CR, Barraza A, Magallón-barajas FJ,  
472 Chávez-sánchez A, et al. Silver nanoparticles enhance survival of white spot syndrome virus  
473 infected *Penaeus vannamei* shrimps by activation of its immunological system. *Fish*  
474 *Shellfish Immunol*. 2019;84: 1083–1089. doi:10.1016/j.fsi.2018.10.007

475 24. Borrego B, Lorenzo G, Mota-Morales JD, Almanza-Reyes H, Mateos F, López-Gil E, et al.  
476 Potential application of silver nanoparticles to control the infectivity of Rift Valley fever  
477 virus in vitro and in vivo. *Nanomedicine Nanotechnology, Biol Med*. 2016;12.  
478 doi:10.1016/j.nano.2016.01.021

479 25. Borrego B, Lorenzo G, Almanza H, Mateos F, López-Gil E, De La Losa N, et al. Application of  
480 silver nanoparticles to control Rift Valley fever virus infection in vitro and in vivo.

481 26. Salleh A, Naomi R, Utami ND, Mohammad AW, Mahmoudi E, Mustafa N, et al. The Potential  
482 of Silver Nanoparticles for Antiviral and Antibacterial Applications: A Mechanism of Action.  
483 *Nanomater (Basel, Switzerland)*. 2020;10. doi:10.3390/nano10081566

484 27. Cardoso VS, Quelemes P V, Amorin A, Primo FL, Gobo GG, Tedesco AC, et al. Collagen-  
485 based silver nanoparticles for biological applications: synthesis and characterization. *J*  
486 *Nanobiotechnology*. 2014;12: 36. doi:10.1186/s12951-014-0036-6

487 28. Jeremiah SS, Miyakawa K, Morita T, Yamaoka Y, Ryo A. Potent antiviral effect of silver  
488 nanoparticles on SARS-CoV-2. *Biochem Biophys Res Commun*. 2020;533: 195–200.

- 489           doi:10.1016/j.bbrc.2020.09.018
- 490    29.    CDC. Handwashing | CDC. In: Handwashing [Internet]. [cited 12 Sep 2020]. Available:  
491           <https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/handwashing.html>
- 492    30.    Schwartz J, King C-C, Yen M-Y. Protecting Healthcare Workers During the Coronavirus  
493           Disease 2019 (COVID-19) Outbreak: Lessons From Taiwan’s Severe Acute Respiratory  
494           Syndrome Response. *Clin Infect Dis*. 2020;71: 858–860. doi:10.1093/cid/ciaa255
- 495    31.    Casale M, Rinaldi V, Sabatino L, Moffa A, Ciccozzi M. Could nasal irrigation and oral rinse  
496           reduce the risk for COVID-19 infection? *International journal of immunopathology and*  
497           *pharmacology*. England; 2020. p. 2058738420941757. doi:10.1177/2058738420941757
- 498    32.    Singh S, Sharma N, Singh U, Singh T, Mangal DK, Singh V. Nasopharyngeal wash in  
499           preventing and treating upper respiratory tract infections: Could it prevent COVID-19?  
500           2020. doi:10.4103/lungindia.lungindia
- 501    33.    Edgardo F. Can a Nasal / Oral / Ocular Spray Inactivate and Prevent SARS-CoV-2 infection?  
502           A Can a Nasal / Oral / Ocular Spray Inactivate and Prevent SARS-CoV-2 infection? A  
503           hypothesis. *Int J Odontostomat*. 2020; 2–5.
- 504    34.    To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C, et al. Consistent Detection of  
505           2019 Novel Coronavirus in Saliva. *Clin Infect Dis*. 2020;71: 841–843.  
506           doi:10.1093/cid/ciaa149
- 507    35.    Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls  
508           in dental practice. *Int J Oral Sci*. 2020;12: 9. doi:10.1038/s41368-020-0075-9
- 509    36.    Khan MM, Parab SR, Paranjape M. Repurposing 0.5% povidone iodine solution in

510 otorhinolaryngology practice in Covid 19 pandemic. Am J Otolaryngol. 2020;41: 102618.

511 doi:<https://doi.org/10.1016/j.amjoto.2020.102618>

512 37. Butowt R, Bilinska K. SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for

513 Clinical Samples Allowing Earlier Virus Detection. ACS Chem Neurosci. 2020; 3–6.

514 doi:[10.1021/acscemneuro.0c00172](https://doi.org/10.1021/acscemneuro.0c00172)

515 38. Uskoković V. Why have nanotechnologies been underutilized in the global uprising against

516 the coronavirus pandemic? Nanomedicine (Lond). 2020;15: 1719–1734. doi:[10.2217/nnm-](https://doi.org/10.2217/nnm-2020-0163)

517 [2020-0163](https://doi.org/10.2217/nnm-2020-0163)

518